Marengo Therapeutics

Clinical-stage biotechnology company developing novel T cell-engaging immunotherapies for cancer, including the lead candidate Invikafusp alfa (STAR0602) for PD-1-resistant solid tumors.

Location
Cambridge, Massachusetts, USA
Founded
2018
Investors
1
Categories
biotech, immunotherapy, oncology, cancer, biologics

Investors

NameLocationTypeStagesPortfolio
Apple Tree PartnersNew York, USAbiotech-focused
series-aseries-b+2
23